Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Wells Fargo & Co (WFC) Price & Performance

Inovio Pharmaceuticals IncTrade
Wells Fargo & CoTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Wells Fargo & Co — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Wells Fargo & Co trades at $89.03 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 3369.3× Inovio Pharmaceuticals Inc's market cap, and Wells Fargo & Co pays a 2.29% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

INOWFC
Market Cap
$78.55M$264.66B
Sector
HealthFinancials
52-Week High
$2.87$96.40
52-Week Low
$0.66$73.42
Enterprise Value
$49.56M
Dividend Yield
2.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Wells Fargo & Co

Wells Fargo (WFC) trades at $89.15, up 1.82% for the day, with a bullish technical signal from moving averages and a consensus analyst price target of $97.64. Recent earnings show a Q2 2026 beat but misses in prior quarters, while revenue and net income have grown steadily from 2022 to 2025. The company is expanding into digital services like tokenized deposits, announced in August 2026, to enhance corporate client offerings.

The stock presents a value opportunity with a P/E of 12.72 and strong profitability metrics, including a 25.97% net income margin. Risks include volatile cash flows, with operating cash flow negative in 2025, and competitive pressures in banking. Analyst sentiment is mixed but leans positive, with 45% buy ratings, supporting potential upside if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Wells Fargo & Co

Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.

Read more on WFC